NCT00448435View on ClinicalTrials.gov

Clinical Assessment Of GW815SF HFA MDI In Pediatric Patients With Bronchial Asthma

PHASE3CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

January 31, 2008

Study Completion Date

January 31, 2008

Conditions
Bronchial Asthma
Interventions
DRUG

GW815SF HFA MDI

salmeterol and fluticasone propionate combination

DRUG

salmeterol and fluticasone propionate

salmeterol + fluticasone propionate

Trial Locations (8)

260-0001

GSK Investigational Site, Chiba

245-0018

GSK Investigational Site, Kanagawa

360-0018

GSK Investigational Site, Saitama

360-0812

GSK Investigational Site, Saitama

154-0002

GSK Investigational Site, Tokyo

154-0017

GSK Investigational Site, Tokyo

158-0083

GSK Investigational Site, Tokyo

158-0097

GSK Investigational Site, Tokyo

Sponsors

Lead Sponsor

GlaxoSmithKline
All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY